Schaeffer Evelin L, Gattaz Wagner F
Department and Institute of Psychiatry, Laboratory of Neuroscience (LIM-27), Faculty of Medicine, University of São Paulo, Rua Dr. Ovídio Pires de Campos 785, 05403-010, Sao Paulo, SP, Brazil.
Psychopharmacology (Berl). 2008 May;198(1):1-27. doi: 10.1007/s00213-008-1092-0. Epub 2008 Feb 19.
Alzheimer disease (AD), a progressive neurodegenerative disorder, is the leading cause of dementia in the elderly. A combination of cholinergic and glutamatergic dysfunction appears to underlie the symptomatology of AD, and thus, treatment strategies should address impairments in both systems. Evidence suggests the involvement of phospholipase A(2) (PLA(2)) enzyme in memory impairment and neurodegeneration in AD via actions on both cholinergic and glutamatergic systems.
To review cholinergic and glutamatergic alterations underlying cognitive impairment and neuropathology in AD and attempt to link PLA(2) with such alterations.
Medline databases were searched (no date restrictions) for published articles with links among the terms Alzheimer disease (mild, moderate, severe), mild cognitive impairment, choline acetyltransferase, acetylcholinesterase, NGF, NGF receptor, muscarinic receptor, nicotinic receptor, NMDA, AMPA, metabotropic glutamate receptor, atrophy, glucose metabolism, phospholipid metabolism, sphingolipid, membrane fluidity, phospholipase A(2), arachidonic acid, attention, memory, long-term potentiation, beta-amyloid, tau, inflammation, and reactive species. Reference lists of the identified articles were checked to identify additional studies of interest.
Overall, results suggest the hypothesis that persistent inhibition of cPLA(2) and iPLA(2) isoforms at early stages of AD may play a central role in memory deficits and beta-amyloid production through down-regulation of cholinergic and glutamate receptors. As the disease progresses, beta-amyloid induced up-regulation of cPLA(2) and sPLA(2) isoforms may play critical roles in inflammation and oxidative stress, thus participating in the neurodegenerative process.
Activation and inhibition of specific PLA(2) isoforms at different stages of AD could be of therapeutic importance and delay cognitive dysfunction and neurodegeneration.
阿尔茨海默病(AD)是一种进行性神经退行性疾病,是老年人痴呆的主要原因。胆碱能和谷氨酸能功能障碍共同作用似乎是AD症状的基础,因此,治疗策略应针对这两个系统的损伤。有证据表明,磷脂酶A2(PLA2)通过作用于胆碱能和谷氨酸能系统参与AD的记忆损害和神经退行性变。
综述AD认知障碍和神经病理学背后的胆碱能和谷氨酸能改变,并尝试将PLA2与这些改变联系起来。
检索Medline数据库(无日期限制),查找在阿尔茨海默病(轻度、中度、重度)、轻度认知障碍、胆碱乙酰转移酶、乙酰胆碱酯酶、神经生长因子(NGF)、NGF受体、毒蕈碱受体、烟碱受体、N-甲基-D-天冬氨酸(NMDA)、α-氨基-3-羟基-5-甲基-4-异恶唑丙酸(AMPA)、代谢型谷氨酸受体、萎缩、葡萄糖代谢、磷脂代谢、鞘脂、膜流动性、磷脂酶A2、花生四烯酸、注意力、记忆、长时程增强、β-淀粉样蛋白、tau蛋白、炎症和活性物质等术语之间有联系的已发表文章。检查已识别文章的参考文献列表,以识别其他感兴趣的研究。
总体而言,结果提示这样一种假说,即在AD早期持续抑制胞质型磷脂酶A2(cPLA2)和内膜型磷脂酶A2(iPLA2)亚型可能通过下调胆碱能和谷氨酸受体在记忆缺陷和β-淀粉样蛋白产生中起核心作用。随着疾病进展,β-淀粉样蛋白诱导的cPLA2和分泌型磷脂酶A2(sPLA2)亚型上调可能在炎症和氧化应激中起关键作用,从而参与神经退行性变过程。
在AD的不同阶段激活和抑制特定的PLA2亚型可能具有治疗意义,并延缓认知功能障碍和神经退行性变。